NEWS New Project: TUBITAK 1001 Our post-doctoral researcher Dr. Cansel Vatansever’s research project, “Modification of Hypervirulant Klebsiella pneumoniae virulence with CRISPR/Cas9 for real-time monitorization of sepsis pathogenesis in an in vivo mouse sepsis model,” was approved as a TUBITAK 1001 project. We congratulate our researcher.

PUBLICATION COVID-19 in Transplant Patients: A Multi-Centered Study Since the beginning of the pandemic, the novel coronavirus (SARS-CoV-2) has infected approximately 635 million individuals and caused almost 6.5 million deaths worldwide. KUISCID researchers analyzed the neutralizing antibody response among transplant patients who were immunosuppressed. Their study “BNT162b2 or CoronaVac as the Third Dose against Omicron: Neutralizing Antibody Responses among Transplant Recipients Who Had Received Two Doses of CoronaVac” was published in “Viruses”. Click for the article.

NEWS New Variants COVID-19 cases have started to increase once more both in our country & worldwide. One of the main causes of this increase is the Eris variant. Here is a follow-up for all the questions in mind. Click to listen.

NEWS Meeting with our National and International Partners KUISCID, in collaboration with Oxford University organized a meeting with national and international partners to discuss the details of a new project for global antibiotic resistance. Such collaborative projects enhance our reputation worldwide as well as bring up new funds for research. Follow our monthly newsletter for the upcoming steps of our project.